Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
2
NRC Quote, Financials, Valuation and Earnings
Last price:
$12.87
Seasonality move
:
-3.83%
Day range:
$13.12 - $14.96
52-week range:
$9.76 - $22.79
Dividend yield:
3.78%
P/E ratio:
27.15x
P/S ratio:
2.24x
P/B ratio:
22.25x
Volume:
200.9K
Avg. volume:
101.8K
1-year change:
-21.52%
Market cap:
$311.3M
Revenue:
$137.4M
EPS (TTM):
$0.51
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, National Research Corp. has -- downside to fair value with a price target of -- per share.
NRC vs. S&P 500
-
Over the past 5 trading days, National Research Corp. has underperformed the S&P 500 by -10.07% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
National Research Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
National Research Corp. revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter National Research Corp. reported revenues of $35.2M.
Earnings Growth
-
National Research Corp. earnings have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter National Research Corp. reported earnings per share of $0.08.
Enterprise value:
386.2M
EV / Invested capital:
4.15x
Price / LTM sales:
2.24x
EV / EBIT:
17.09x
EV / Revenue:
2.81x
PEG ratio (5yr expected):
5.51x
EV / Free cash flow:
24.53x
Price / Operating cash flow:
19.56x
Enterprise value / EBITDA:
12.78x
Gross Profit (TTM):
$77.4M
Return On Assets:
8.3%
Net Income Margin (TTM):
8.29%
Return On Equity:
51.49%
Return On Invested Capital:
11.87%
Operating Margin:
13.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $148.6M | $143.1M | $137.4M | $36.9M | $35.2M | |
| Gross Profit | $86.7M | $80.1M | $77.4M | $21M | $19.1M | |
| Operating Income | $40.1M | $35.5M | $22.6M | $9.7M | $4.7M | |
| EBITDA | $46M | $41.5M | $30.2M | $11.2M | $6.8M | |
| Diluted EPS | $1.26 | $1.04 | $0.51 | $0.28 | $0.08 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $73.7M | $43.7M | $24.4M | $19.6M | $20.2M | |
| Total Assets | $157.5M | $130.5M | $122.4M | $139.2M | $134.9M | |
| Current Liabilities | $40.4M | $33.4M | $36.2M | $35.9M | $36.6M | |
| Total Liabilities | $72.2M | $58.4M | $73.5M | $107.9M | $120.9M | |
| Total Equity | $85.3M | $72M | $49M | $31.3M | $14M | |
| Total Debt | $28.2M | $22.9M | $38.4M | $63.8M | $79M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $38.1M | $34.6M | $26.5M | $6.4M | $7.2M | |
| Cash From Investing | -$15.8M | -$20.3M | -$10.7M | -$4.4M | -$1.1M | |
| Cash From Financing | -$40.7M | -$16.8M | -$15.8M | -$1.2M | -$4.1M | |
| Free Cash Flow | $22.3M | $19.2M | $15.7M | $1.9M | $6.1M | |
NRC
Sector
Market Cap
$311.3M
$23.4M
Price % of 52-Week High
60.33%
48.88%
Dividend Yield
3.78%
0%
Shareholder Yield
6.29%
-1.64%
1-Year Price Total Return
-21.52%
-21.81%
Beta (5-Year)
0.490
0.504
Dividend yield:
3.78%
Annualized payout:
$0.52
Payout ratio:
194.18%
Growth streak:
1 years
Technicals
8-day SMA
Sell
Level
$16.29
200-day SMA
Sell
Level
$15.50
Bollinger Bands (100)
Sell
Level
13.01 - 19.33
Chaikin Money Flow
Sell
Level
-593K
20-day SMA
Sell
Level
$19.18
Relative Strength Index (RSI14)
Sell
Level
28.84
ADX Line
Sell
Level
31.09
Williams %R
Buy
Level
-92.9054
50-day SMA
Sell
Level
$18.58
MACD (12, 26)
Sell
Level
-1.23
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
7.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.3547)
Sell
CA Score
(Annual)
Level (-0.8652)
Buy
Beneish M-Score
(Annual)
Level (-2.9173)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (4.1751)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.
Stock Forecast FAQ
In the current month, NRC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NRC average analyst price target in the past 3 months is --.
-
Where Will National Research Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that National Research Corp. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About National Research Corp.?
Analysts are divided on their view about National Research Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that National Research Corp. is a Sell and believe this share price will rise from its current level to --.
-
What Is National Research Corp.'s Price Target?
The price target for National Research Corp. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NRC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for National Research Corp. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NRC?
You can purchase shares of National Research Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase National Research Corp. shares.
-
What Is The National Research Corp. Share Price Today?
National Research Corp. was last trading at $12.87 per share. This represents the most recent stock quote for National Research Corp.. Yesterday, National Research Corp. closed at $13.75 per share.
-
How To Buy National Research Corp. Stock Online?
In order to purchase National Research Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NRC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NRC
Sector
P/E ratio
27.15x
23.34x
PEG ratio
5.51x
-0.01x
P/B ratio
22.25x
1.72x
Price / LTM sales
2.24x
1.51x
Growth Metrics
NRC
Sector
Revenue growth
-4.64%
3.21%
Earnings growth
-70.66%
10.12%
Revenue (5-year growth)
0.61%
6.27%
Earnings forecast
--
-$0.19
Profitability
NRC
Sector
Profitability FY 2025
$77.4M
$2.7M
Return on invested capital
11.87%
-33.62%
Return on assets
8.3%
-29.68%
Return on equity
51.49%
-38.89%
Earnings Date
Last Earnings Date
Feb
3
Next Earnings Date
Apr
27
Estimated Next Earnings Date
May
5
Balance Sheet
NRC
Sector
Total cash
$4.1M
$25M
Short term investments
--
$23.9M
Total assets
$134.9M
$72.8M
Long term debt
$79M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
